Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Senior Vice Minister Tsuji, Parliamentary Secretary Fujita in Charge of Medical, Nursing Fee Revision
September 7, 2011
- Dr Kondo of PMDA Presents Example of Successful Use of Regulatory Science
September 6, 2011
- Pharmaceutical Industry Fully Sufficient as Export Industry: METI Minister Hachiro
September 5, 2011
- MHLW Minister Komiyama to Focus on Social Security Reform
September 5, 2011
- Noda Cabinet: MHLW Vice Minister Komiyama Promoted to Minister
September 5, 2011
- New EAD Director Kamata Supports Making Premium for New Drug Development Permanent
September 5, 2011
- METI to Establish New Company to Support Medical Tourism from Overseas
September 5, 2011
- Avastin Recommended for Approval for Breast Cancer
September 5, 2011
- Fingolimod Recommended for Approval
September 5, 2011
- Make the Premium for New Drug Development Permanent: FPMAJ, PhRMA, EFPIA Japan
September 5, 2011
- Increases in Social Security Spending to Be Covered by Cuts in Other Spending: FY2012 Budget
September 5, 2011
- US FDA Approves Vemurafenib for Melanoma; to Be Copromoted by Daiichi Sankyo
September 5, 2011
- Patent Office to Revise GL for Application of Patent Extension System
September 5, 2011
- Korosho to Apply for PIC/S Membership in Early FY2012: New CND Director Nakaigawa
September 5, 2011
- Almarl or Amaryl Should Be Renamed to Prevent Mistakes: MHLW
September 1, 2011
- Anticancer Drug Dispensed Instead of Norvasc Generic: MHLW Report
September 1, 2011
- Upgrading Quality Both in Facilities, Research for ICH-GCP: RDD Director Sahara
September 1, 2011
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…